{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:50:29Z","timestamp":1762912229322,"version":"3.45.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/j.prdoa.2019.11.005","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T21:33:14Z","timestamp":1575408794000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Treatment of dystonia and tics"],"prefix":"10.1016","volume":"2","author":[{"given":"Steven","family":"Bellows","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2019.11.005_bb0005","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/CON.0000000000000747","article-title":"The dystonias","volume":"25","author":"Jinnah","year":"2019","journal-title":"Continuum (Minneap. Minn)"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1212\/WNL.0000000000003596","article-title":"Dystonia coalition investigators, dystonia treatment: patterns of medication use in an international cohort","volume":"88","author":"Pirio Richardson","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/21678707.2017.1366309","article-title":"Available treatment options for dystonia","volume":"5","author":"Alfradique-Dunham","year":"2017","journal-title":"Expert Opin. Orphan Drugs."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1212\/WNL.36.2.160","article-title":"Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl","volume":"36","author":"Burke","year":"1986","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archneur.1995.00540280095022","article-title":"Diphenhydramine is effective in the treatment of idiopathic dystonia","volume":"52","author":"Truong","year":"1995","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41572-018-0023-6","article-title":"Dystonia","volume":"4","author":"Balint","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","article-title":"Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study","volume":"11","author":"Jankovic","year":"1982","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1756285616677004","article-title":"Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study","volume":"10","author":"Miguel","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0050","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.parkreldis.2014.09.029","article-title":"Treatment of myoclonus-dystonia syndrome with tetrabenazine","volume":"20","author":"Luciano","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0055","doi-asserted-by":"crossref","unstructured":"H.A. Hanagasi, B. Bilgic, H. Gurvit, M. Emre, Clozapine treatment in oromandibular dystonia., Clin. Neuropharmacol. 27 (n.d.) 84\u20136. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15252269.","DOI":"10.1097\/00002826-200403000-00007"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0060","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/1531-8257(199907)14:4<652::AID-MDS1015>3.0.CO;2-G","article-title":"An open trial of clozapine for dystonia","volume":"14","author":"Karp","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0065","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1212\/WNL.44.5.957","article-title":"Clozapine treatment of spasmodic torticollis","volume":"44","author":"Thiel","year":"1994","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0070","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13311-013-0231-4","article-title":"Treatment of dystonia","volume":"11","author":"Thenganatt","year":"2014","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2217\/nmt-2018-0047","article-title":"Update on current and emerging therapies for dystonia","volume":"9","author":"Lizarraga","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0080","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp.41.8.707","article-title":"Baclofen in Parkinson's disease","volume":"41","author":"Lees","year":"1978","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0085","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1017\/S0012162201001190","article-title":"Intrathecal baclofen for generalized dystonia","volume":"43","author":"Albright","year":"2001","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.25498","article-title":"The effect of intrathecal baclofen in dyskinetic cerebral palsy: the IDYS trial","volume":"86","author":"Bonouvri\u00e9","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0095","first-page":"58","article-title":"Efficacy of zolpidem for dystonia: a study among different subtypes","volume":"3","author":"Miyazaki","year":"2012","journal-title":"Front. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0100","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3389\/fneur.2019.00779","article-title":"Zolpidem for the treatment of dystonia","volume":"10","author":"Badillo","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0105","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3389\/fneur.2017.00559","article-title":"Dystonic dysarthria in Wilson disease: efficacy of zolpidem","volume":"8","author":"Poujois","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0110","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.58.4.662","article-title":"Zolpidem improves dystonia in \u201cLubag\u201d or X-linked dystonia-parkinsonism syndrome","volume":"58","author":"Evidente","year":"2002","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0115","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1212\/WNL.0000000000002631","article-title":"A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia","volume":"86","author":"Hainque","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2016.11.029","article-title":"Treatment of blepharospasm with apraclonidine","volume":"372","author":"Vijayakumar","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0125","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/mds.20605","article-title":"A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders","volume":"20","author":"Frucht","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0130","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/lary.26381","article-title":"An open-label study of sodium oxybate in spasmodic dysphonia","volume":"127","author":"Rumbach","year":"2017","journal-title":"Laryngoscope."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/mds.1200","article-title":"Riluzole therapy in cervical dystonia","volume":"17","author":"M\u00fcller","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/ane.12701","article-title":"Lack of efficacy of levetiracetam in oromandibular and cranial dystonia","volume":"136","author":"Park","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2014.12.030","article-title":"Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE)","volume":"349","author":"Jankovic","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.toxicon.2017.09.004","article-title":"Longitudinal studies of botulinum toxin in cervical dystonia: why do patients discontinue therapy?","volume":"147","author":"Jinnah","year":"2018","journal-title":"Toxicon."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/toxins11090491","article-title":"Immunogenicity associated with botulinum toxin treatment","volume":"11","author":"Bellows","year":"2019","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0170","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0175","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000067023","article-title":"Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis","volume":"49","author":"Dressler","year":"2003","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0180","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00702-018-1960-7","article-title":"Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis","volume":"126","author":"Dadgardoust","year":"2019","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0185","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1212\/WNL.0000000000004951","article-title":"Onabotulinum toxin-A injections for sleep bruxism: a double-blind, placebo-controlled study","volume":"90","author":"Ondo","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0190","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0195","doi-asserted-by":"crossref","unstructured":"J. Jankovic, D. Truong, A.T. Patel, A. Brashear, M. Evatt, R.G. Rubio, C.K. Oh, D. Snyder, G. Shears, C. Comella, Injectable daxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study., Mov. Disord. Clin. Pract. 5 (2018) 273\u2013282. doi:https:\/\/doi.org\/10.1002\/mdc3.12613, (in press).","DOI":"10.1002\/mdc3.12613"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.toxicon.2011.05.012","article-title":"Characterization of diffusion and duration of action of a new botulinum toxin type A formulation","volume":"58","author":"Stone","year":"2011","journal-title":"Toxicon."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0215","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.parkreldis.2017.09.008","article-title":"Failure of pallidal deep brain stimulation in DYT12-ATP1A3 dystonia","volume":"45","author":"Albanese","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0220","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/ene.13762","article-title":"Dystonia: diagnosis and management","volume":"26","author":"Albanese","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0225","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00701-015-2646-7","article-title":"Different clinical course of pallidal deep brain stimulation for phasic- and tonic-type cervical dystonia","volume":"158","author":"Chung","year":"2016","journal-title":"Acta Neurochir. (Wien)."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0230","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0000000000002370","article-title":"Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia","volume":"86","author":"Pouclet-Courtemanche","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0235","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.brs.2018.08.006","article-title":"DBS study group for dystonia, Neurostimulation in tardive dystonia\/dyskinesia: a delayed start, sham stimulation-controlled randomized trial","volume":"11","author":"Gruber","year":"2018","journal-title":"Brain Stimul."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0240","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1474-4422(07)70035-2","article-title":"Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study","volume":"6","author":"Vidailhet","year":"2007","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0245","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1474-4422(12)70257-0","article-title":"Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial","volume":"11","author":"Volkmann","year":"2012","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0250","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/brain\/awm229","article-title":"The Canadian multicentre study of deep brain stimulation for cervical dystonia","volume":"130","author":"Kiss","year":"2007","journal-title":"Brain."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0255","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(14)70143-7","article-title":"Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial","volume":"13","author":"Volkmann","year":"2014","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0260","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3171\/2013.8.JNS13844","article-title":"A randomized double-blind crossover trial comparing subthalamic and pallidal deep brain stimulation for dystonia","volume":"119","author":"Schjerling","year":"2013","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0265","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/mds.25586","article-title":"Subthalamus deep brain stimulation for primary dystonia patients: a long-term follow-up study","volume":"28","author":"Cao","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1212\/WNL.0000000000003451","article-title":"Subthalamic nucleus deep brain stimulation in isolated dystonia: a 3-year follow-up study","volume":"88","author":"Ostrem","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0275","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.parkreldis.2018.05.024","article-title":"Subthalamic deep brain stimulation in patients with primary dystonia: a ten-year follow-up study","volume":"55","author":"Deng","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0280","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3389\/fneur.2018.01008","article-title":"Stereotactic lesioning of the thalamic Vo nucleus for the treatment of Writer's cramp (focal hand dystonia)","volume":"9","author":"Shimizu","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0285","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.49.4.1173","article-title":"Stereotactic selective Vo-complex thalamotomy in a patient with dystonic writer's cramp","volume":"49","author":"Goto","year":"1997","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0290","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000075165","article-title":"Stereotactic ventrooralis thalamotomy for task-specific focal hand dystonia (writer's cramp)","volume":"80","author":"Taira","year":"2003","journal-title":"Stereotact. Funct. Neurosurg."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0295","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.23877","article-title":"Long-term improvement of musician's dystonia after stereotactic ventro-oral thalamotomy","volume":"74","author":"Horisawa","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.wneu.2016.05.017","article-title":"Bilateral stereotactic thalamotomy for bilateral musician's hand dystonia","volume":"92","author":"Horisawa","year":"2016","journal-title":"World Neurosurg."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0305","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/mds.26726","article-title":"Gamma knife ventro-oral thalamotomy for musician's dystonia","volume":"32","author":"Horisawa","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0310","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/mdc3.12398","article-title":"Stereotactic thalamotomy for task-specific dystonia","volume":"4","author":"Doshi","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0315","series-title":"Safety and Long-term Efficacy of Ventro-oral Thalamotomy for Focal Hand Dystonia","volume":"0","author":"Horisawa","year":"2019"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0320","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1212\/WNL.0000000000006818","article-title":"Safety and long-term efficacy of ventro-oral thalamotomy for focal hand dystonia: a retrospective study of 171 patients","volume":"92","author":"Horisawa","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0325","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neubiorev.2012.09.008","article-title":"Systematic review: pharmacological treatment of tic disorders\u2013efficacy of antipsychotic and alpha-2 adrenergic agonist agents","volume":"37","author":"Weisman","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0330","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","article-title":"Treatment of ADHD in children with tics: a randomized controlled trial","volume":"58","author":"Tourette's Syndrome Study Group","year":"2002","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0335","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1089\/cap.2017.0024","article-title":"Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders","volume":"27","author":"Murphy","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0340","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/WNF.0b013e3181c295c1","article-title":"Topiramate in treatment of tourette syndrome","volume":"33","author":"Kuo","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0345","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","article-title":"A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome","volume":"81","author":"Jankovic","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0350","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.pediatrneurol.2013.05.002","article-title":"Topiramate for Tourette's syndrome in children: a meta-analysis","volume":"49","author":"Yang","year":"2013","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0355","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1089\/cap.2016.0026","article-title":"Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette's disorder in children and adolescents","volume":"27","author":"Sallee","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0360","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.0000000000007467","article-title":"Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders","volume":"92","author":"Pringsheim","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0365","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1212\/WNL.0000000000007466","article-title":"Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders","volume":"92","author":"Pringsheim","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0370","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.2010.607","article-title":"Behavior therapy for children with Tourette disorder: a randomized controlled trial","volume":"303","author":"Piacentini","year":"2010","journal-title":"JAMA."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0375","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/archgenpsychiatry.2011.1528","article-title":"Randomized trial of behavior therapy for adults with Tourette syndrome","volume":"69","author":"Wilhelm","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0380","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14737175.2018.1403899","article-title":"Treatment options for chorea","volume":"18","author":"Bashir","year":"2018","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0385","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0390","doi-asserted-by":"crossref","first-page":"422","DOI":"10.5334\/tohm.287","article-title":"Deutetrabenazine in tics associated with Tourette syndrome","volume":"6","author":"Jankovic","year":"2016","journal-title":"Tremor Other Hyperkinet. Mov. (N. Y)"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0420","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.27457","article-title":"Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: a randomized, placebo-controlled crossover study","volume":"33","author":"Gilbert","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0425","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/WNF.0000000000000017","article-title":"A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome","volume":"37","author":"Gilbert","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0435","article-title":"Treatment of tics associated with Tourette syndrome","author":"Jankovic","year":"2019","journal-title":"J Neural Transm."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0440","doi-asserted-by":"crossref","first-page":"9059","DOI":"10.1021\/acs.jmedchem.8b01405","article-title":"Activity-based protein profiling delivers selective drug candidate ABX-1431, a monoacylglycerol lipase inhibitor, to control lipid metabolism in neurological disorders","volume":"61","author":"Jiang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0455","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","article-title":"Botulinum toxin in the treatment of tics","volume":"57","author":"Kwak","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0460","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10072-003-0201-4","article-title":"Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A","volume":"24","author":"Porta","year":"2004","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0465","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","article-title":"Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial","volume":"56","author":"Marras","year":"2001","journal-title":"Neurology."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0470","article-title":"Botulinum toxin for motor and phonic tics in Tourette's syndrome","volume":"1","author":"Pandey","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0475","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0480","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamaneurol.2017.4317","article-title":"Efficacy and safety of deep brain stimulation in Tourette syndrome: the international Tourette syndrome deep brain stimulation public database and registry","volume":"75","author":"Martinez-Ramirez","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0485","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3171\/2018.7.PEDS18300","article-title":"Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data","volume":"23","author":"Coulombe","year":"2018","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0490","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2147\/NDT.S139368","article-title":"Deep brain stimulation in Tourette's syndrome: evidence to date","volume":"15","author":"Casagrande","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0495","doi-asserted-by":"crossref","unstructured":"J.C. Baldermann, T. Sch\u00fcller, D. Huys, I. Becker, L. Timmermann, F. Jessen, V. Visser-Vandewalle, J. Kuhn, Deep brain stimulation for Tourette-syndrome: a systematic review and meta-analysis., Brain Stimul. 9 (n.d.) 296\u2013304. https:\/\/doi.org\/10.1016\/j.brs.2015.11.005.","DOI":"10.1016\/j.brs.2015.11.005"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0500","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1176\/appi.ajp.2012.11101583","article-title":"Deep brain stimulation of anteromedial globus pallidus interna for severe Tourette's syndrome","volume":"169","author":"Cannon","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.prdoa.2019.11.005_bb0505","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/mds.23734","article-title":"Deep brain stimulation for Gilles de la Tourette syndrome: a case series targeting subregions of the globus pallidus internus","volume":"26","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.prdoa.2019.11.005_bb0510","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S1474-4422(17)30160-6","article-title":"Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial","volume":"16","author":"Welter","year":"2017","journal-title":"Lancet. Neurol."},{"year":"2019","series-title":"BOTOX\u00ae [Package Insert]","key":"10.1016\/j.prdoa.2019.11.005_bb0515"},{"year":"2016","series-title":"DYSPORT\u00ae [Package Insert]","key":"10.1016\/j.prdoa.2019.11.005_bb0520"},{"year":"2018","series-title":"XEOMIN\u00ae [Package Insert]","key":"10.1016\/j.prdoa.2019.11.005_bb0525"},{"year":"2009","series-title":"MYOBLOC\u00ae [Package Insert]","key":"10.1016\/j.prdoa.2019.11.005_bb0530"}],"container-title":["Clinical Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112519300313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112519300313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:45:27Z","timestamp":1762911927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112519300313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":94,"alternative-id":["S2590112519300313"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2019.11.005","relation":{},"ISSN":["2590-1125"],"issn-type":[{"type":"print","value":"2590-1125"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of dystonia and tics","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2019.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}